Amgen's Vectibix nabs new use in Europe; Mylan launches first generic of Warner Chilcott contraceptive;

@FiercePharma: Medtronic settles DoJ charges for $4.1M on spinal device sales in Malaysia, China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Layoffs for manufacturing units at Amgen, Novartis contributed to sizable cuts last year. Check out the new feature | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals. Report | Follow @CarlyHFierce

> Amgen's ($AMGN) colon cancer drug Vectibix won broader approval in Europe, as a first-line treatment in certain patients, in combination with a chemotherapy regimen called FOLFIRI. Report

> Mylan ($MYL) rolled out its version of Generess Fe, a contraceptive brand marketed by Warner Chilcott; it's the first generic form of the product. Report

> AbbVie ($ABBV) asked a U.S. judge to dismiss claims by Shire ($SHPG) shareholders, who say the Illinois-based company misrepresented the importance of tax incentives in its aborted agreement to buy Shire. Report

> A U.S. judge tossed out one the few remaining thalidomide cases against GlaxoSmithKline ($GSK), Legal Intelligencer reports. Article

> Roche's ($RHHBY) Rituxan, approved to treat blood cancers and rheumatoid arthritis, could be a treatment option for a rare disease known as eosinophilic granulomatosis and polyangiitis (EGPA), a study found. Report

Medical Device News

@FierceMedDev: Check out the top med tech companies of 2014. Feature | Follow @FierceMedDev

@VarunSaxena2: Experts: Stent retrieval devices to play larger role in treatment of stroke. Story | Follow @VarunSaxena2

@EmilyWFierce: Natera ropes in $55M with eye on cancer Dx. FierceDiagnostics article | Follow @EmilyWFierce

> Miniaturized skin cancer device emerges as alternative to surgery. Article

> J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery. Report

Biotech News

@FierceBiotech: High-flying immuno-oncology player Adaptimmune pitches $150M IPO. News | Follow @FierceBiotech

@JohnCFierce: Plotting a course for True North, biotech CEO steps up with a $35M round. Report | Follow @JohnCFierce

> CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub. More

> Merck wagers $434M on Arvinas and its protein-disposal system. Report

> Ocular Therapeutix plunges as eye treatment blurs the line in PhIII. Article

> Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. News

Drug Delivery News

> Gold nanoparticles deliver RNA to the brain to suppress cancer genes. Story

> Developer of Botox lotion files for $58M IPO. Item

> Researchers take aim at childhood neuroblastoma with targeted nanoparticles. More

> Actavis' drug delivery-focused spinoff on the prowl for acquisitions. Report

> AstraZeneca gets FDA nod for alternative administration of oral heart med. Article

Pharma Manufacturing News

> AMRI moves forward with plan to close Wales API plant, cut 62 jobs. Item

> Baxter recalls more than half a million units of saline. News

> North Carolina compounder is closed and its products are recalled. Story

> India's Mankind Pharma investing $16M in API plant. Article

> UAE drug distributor building a $20M plant in Dubai. Report

Pharma Asia News

> Australia-China researchers eye Asian stroke drug for Alzheimer's disease. Story

> South Korea struggles with healthcare needs of elderly. Report

> Second quarter pharma market outlooks for pan-Asia mixed, India promising. Story

> India's Mankind sees 15th product plant online this year. Article

> Sirtex Medical oncology play still has some thunder Down Under. More

And Finally... The "Baron of Botox," dermatologist Dr. Fredric Brandt, died Sunday at his Florida home; police say he committed suicide. Report